Norwegian pharmaceutical company Ultimovacs said it aimed to raise NOK700 m ( $ 8.7 million ) through an IPO next year to market its immunotherapy cancer drug . “If we document that the vaccine works, it can be combined with other immunotherapy treatments for cancers that are coming, so I expect a substantial demand for licenses ... It also said it hoped to win approval to expand a US trial investigating whether its UV1 vaccine candidate could tackle malignant melanoma alongside Norway ’s Keytruda cancer treatment . Ultimovacs has listed DNB Markets and ABG Sundal Collier as brokers for the IPO and said while it forecast revenue from UV1 by 2022 , earlier income was expected from licensing agreements with other companies .
Norwegian pharmaceutical company Ultimovacs said it aimed to raise NOK700 m ( $ 8.7 million ) through an IPO next year to market its immunotherapy cancer drug . It also said it hoped to win approval to expand a US trial investigating whether its UV1 vaccine candidate could tackle malignant melanoma alongside Norway ’s Keytruda cancer treatment . Ultimovacs has listed DNB Markets and ABG Sundal Collier as brokers for the IPO and said while it forecast revenue from UV1 by 2022 , earlier income was expected from licensing agreements with other companies .